AFPI Responds to HHS and the FDA’s Mifepristone Investigation

Washington, D.C.—Twenty-five years ago, the Food and Drug Administration (FDA) approved mifepristone, a chemical abortion pill. Today, the U.S. Department of Health & Human Services (HHS) and the FDA announced a new investigation into the dangers of the drug. America First Policy Institute (AFPI) experts released the following joint statement, applauding this announcement:

“We commend HHS and the FDA for taking steps to review the safety of the abortion drug mifepristone, which is now used in roughly 60% of abortions in the U.S.,” said Dr. Jennifer Bauwens, Director of American Values at AFPI. “This pill puts women at risk of severe medical complications as well as serious mental health consequences, including higher rates of psychiatric hospitalization, substance abuse, and even suicide attempts. Reexamining the approval of mifepristone is an essential step toward protecting both women and their children.”

“Secretary Kennedy and Commissioner Makary know the only way to make Americans healthy again is to make sure what we put into our bodies is actually safe for us to use,” said Hannah Anderson, director of Healthy America and senior director of Policy at AFPI. “Their commitment doesn’t bow to ideological pressure. People have pushed this dangerous pill on women for too long, calling it ‘as safe as Advil’ but we have seen the dangerous complications. I applaud their commitment to gold standard science and a reversal of the pseudoscience that has seriously hurt so many American women.”

“For over 20 years, mifepristone has been destroying the gift of life. Not only does this pill kill unborn children, but it harms the women taking it. We mourn the unborn lives lost and pray for hearts to be turned toward life, and towards safety” said Margo Nicholas, senior policy analyst for American Values at AFPI. “This drug is too dangerous to exist in the marketplace.”